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Abstract
Infection or sterile inflammation triggers site-specific attraction of leukocytes. Leukocyte recruitment is a
process comprising several steps orchestrated by adhesion molecules, chemokines, cytokines and
endogenous regulatory molecules. Distinct adhesive interactions between endothelial cells and
leukocytes and signalling mechanisms contribute to the temporal and spatial fine-tuning of the leukocyte
adhesion cascade. Central players in the leukocyte adhesion cascade include the leukocyte adhesion
receptors of the β2-integrin family, such as the αLβ2 and αMβ2 integrins, or of the β1-integrin family,
such as the α4β1- integrin. Given the central involvement of leukocyte recruitment in different
inflammatory and autoimmune diseases, the leukocyte adhesion cascade in general, and leukocyte
integrins in particular, represent key therapeutic targets. In this context, the present review focuses on the
role of leukocyte integrins in the leukocyte adhesion cascade. Experimental evidence that has implicated
leukocyte integrins as targets in animal models of inflammatory disorders, such as experimental
autoimmune encephalomyelitis, psoriasis, inflammatory bone loss and inflammatory bowel disease as
well as preclinical and clinical therapeutic applications of antibodies that target leukocyte integrins in
various inflammatory disorders are presented. Finally, we review recent findings on endogenous inhibitors
that modify leukocyte integrin function, which could emerge as promising therapeutic targets.
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Infection or sterile inflammation triggers site-specific attraction of leukocytes. Leukocyte
recruitment is a process comprising several steps orchestrated by adhesion molecules, chemokines,
cytokines and endogenous regulatory molecules. Distinct adhesive interactions between
endothelial cells and leukocytes and signalling mechanisms contribute to the temporal and spatial
fine-tuning of the leukocyte adhesion cascade. Central players in the leukocyte adhesion cascade
include the leukocyte adhesion receptors of the !2-integrin family, such as the "L!2 and "M!2
integrins, or of the !1-integrin family, such as the "4!1- integrin. Given the central involvement of
leukocyte recruitment in different inflammatory and autoimmune diseases, the leukocyte adhesion
cascade in general, and leukocyte integrins in particular, represent key therapeutic targets. In this
context, the present review focuses on the role of leukocyte integrins in the leukocyte adhesion
cascade. Experimental evidence that has implicated leukocyte integrins as targets in animal
models of inflammatory disorders, such as experimental autoimmune encephalomyelitis, psoriasis,
inflammatory bone loss and inflammatory bowel disease as well as preclinical and clinical
therapeutic applications of antibodies that target leukocyte integrins in various inflammatory
disorders are presented. Finally, we review recent findings on endogenous inhibitors that modify
leukocyte integrin function, which could emerge as promising therapeutic targets.
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Leukocyte trafficking to sites of injury or infection is tightly regulated by the leukocyte
adhesion cascade. The cascade starts with selectin-dependent leukocyte rolling, followed by
chemokine-induced leukocyte activation and leukocyte slow rolling, mediated by the
collaboration between selectin and integrins and the interactions thereof with their respective
ligands. Slow rolling paves the way for the integrin-dependent steps comprising firm
leukocyte adhesion/arrest, adhesion strengthening and leukocyte crawling on the
endothelium, that finally enable the transendothelial migration of leukocytes mostly through
endothelial junctions to the subendothelium (Figure 1) (Ley et al., 2007; Chavakis, 2012).
The present review will focus particularly on the function of integrins in the leukocyte
adhesion cascade, endogenous factors and molecular mechanisms contributing to the
regulation of integrin activity, animal models, in which the role of integrins in the context of
leukocyte recruitment has been studied, as well as therapeutic approaches targeting
leukocyte integrins in inflammatory diseases.

Integrins; an overview
NIH-PA Author Manuscript

Integrins are a family of adhesion molecules that exist as transmembrane heterodimers,
consisting of one "- and one !-subunit (Hogg et al., 2011; Moser et al., 2009). In mammals,
eighteen " and eight ! subunits have been described, forming 24 different integrin
heterodimers (Herter and Zarbock, 2013; Hynes, 2002).
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Activated integrins participate in mediating cell adhesion; the strength of integrin-mediated
cell adhesion is defined as integrin avidity (Carman and Springer, 2003). Both integrin
affinity and integrin valency contribute to integrin avidity (Carman and Springer, 2003).
Affinity represents the strength of the individual bond between a single integrin and its
ligand and is regulated by the conformational status of integrin subunits, whereas integrin
valency is mediated by the clustering of integrin receptors on the cell surface, thereby
bringing together several individual bonds (Carman and Springer, 2003). In the absence of
activating signals, integrins have an inactive, bent conformation (Askari et al., 2009). Upon
activation by different signals, e.g., deriving from chemokines, or PSGL-1 ligation, integrins
undergo major conformational changes, which results in exposure of their ligand-binding
site in the extracellular domains (Arnaout et al., 2005; Hogg et al., 2011, Moser et al., 2009;
Tiwari et al., 2011; Wegener et al., 2007). Another feature of the process of integrin
activation is its strong dependency on the presence of divalent cations, especially Mn2+ and
Mg2+ ions, which control the conformational changes of the integrin molecules (Gailit and
Ruoslahti, 1988; reviewed in Arnaout et al., 2002; Dransfield et al., 1992; Tiwari et al.,
2011).
In the present review, we will focus on leukocyte integrins, in particular, !2-integrins as well
as integrin "4!1 (very late antigen (VLA)-4; CD49d/CD29) and integrin "4!7 (LPAM-1),
which play a role in leukocyte recruitment and in inflammatory disorders. The !2-integrins
consist of a common ! subunit (CD18) that associates with 4 different " subunits. They
comprise the "L!2-integrin (lymphocyte function-associated antigen 1 [LFA-1]; CD11a/
CD18) and the "M!2-integrin (macrophage-1 antigen [Mac-1] also designated complement
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receptor 3 [CR3]; CD11b/CD18), which are the most crucial !2-integrins for leukocyte
recruitment, as well as the "X!2 (CD11c/CD18; p150,95; CR4) and the "D!2 (CD11d/
CD18) integrins (Chavakis, 2012; Moser et al., 2009). LFA-1 is expressed by neutrophils,
monocytes and lymphocytes, whereas Mac-1 is found mainly on neutrophils and monocytes
and VLA-4 is expressed on monocytes and T lymphocytes (Chan et al., 2001; Hyun et al.,
2009; Chavakis, 2012; Moser et al., 2009). "X!2 is present on macrophages and dendritic
cells (DCs) (O’Doherty et al., 1994; Wu et al., 2009), and "D!2 is expressed on monocytes /
macrophages, especially foam cells, which are macrophages found in atherosclerotic lesions
(Van der Vieren et al., 1995).

The leukocyte adhesion cascade
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The leukocyte adhesion cascade is initiated with leukocyte capture from the blood stream
and rolling on the luminal surface of endothelial cells (Kunkel et al., 1998). Rolling serves
as a break for circulating leukocytes and is mediated by E-, P- and L-selectins (Kansas,
1996, Kuwano et al., 2010). E-selectin and P-selectin are expressed in endothelial cells. Lselectin is constitutively expressed on most leukocytes (McEver, 2002) and plays a
significant role in the migration of naïve and central memory T cells to lymph nodes (von
Andrian and Mempel, 2003). Upon inflammation, the abundance of P- and E-selectin on the
luminal endothelial cell surface is enhanced. Elevated surface expression of endothelial
selectins is mediated either by exocytosis mechanisms in the case of P-selectin, which is
released from cytosolic vesicles (designated Weibel-Palade bodies) or by enhanced
transcriptional gene expression of E-selectin (McEver, 2002). On the other hand, leukocyte
activation results in rapid shedding of L-selectin from their surface (Kishimoto et al., 1989),
which contributes to the modulation of leukocyte rolling velocity (Hafezi-Moghadam and
Ley, 1999).
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Selectins interact with the P-selectin glycoprotein ligand-1 (PSGL-1) (McEver and
Cummings, 1997) as well as other glycosylated ligands, such as CD44 and E-selectin ligand
1 (Hidalgo et al., 2007, reviewed in Zarbock et al., 2011). Leukocyte rolling under flow
conditions is mediated by the rapid formation and dissociation of bonds between selectins
and their ligands (Alon et al, 1995). These transient selectin-dependent adhesive interactions
result in a progressive reduction in the rolling velocity of leukocytes, enabling cells to
receive signals deriving from chemokines present on the endothelial cell surface; these
signals activate integrins, thus allowing subsequent steps of the cascade to take over
(Zarbock et al, 2011).
The interaction between selectins and their ligands leads to intracellular signaling cascades,
which cooperate with chemokine-derived signals, resulting in the activation of integrins and
thus firm leukocyte adhesion (Zarbock et al., 2007a; Yago et al., 2010; Zarbock et al., 2011).
For instance, signalling pathways triggered by E-selectin are mediated by the Src family
kinases Fgr, Hck and Lyn (Yago et al., 2010; Zarbock et al., 2008) also involving the
adaptor proteins DAP12 and FcR# and the spleen tyrosine kinase (Zarbock et al., 2008;
Urzainqui et al., 2002). This pathway results in activation of phospholipase C-#2 (Mueller et
al., 2010; Yago et al., 2010; Zarbock et al., 2011), culminating in the activation of the small
GTPase RAS-related protein 1 (Rap1) (Stadtmann et al., 2011), which can promote integrin
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affinity (Chavakis, 2012). Thus, intracellular signalling induced by PSGL-1 and other
selectin ligands is considered a major driver of the leukocyte adhesion cascade as it
transforms a rolling/selectin-induced signal into activation of leukocyte integrins, thereby
initiating the later steps of the cascade.
Upon activation, integrins mediate firm leukocyte adhesion and crawling. The "4-integrins
VLA-4 and "4!7 as well as the !2-integrins are the most important integrins involved in
leukocyte recruitment (Chavakis, 2012; Berlin et al., 1993) interacting with endothelial
lignads/counter-receptors.
Inflammatory activation of the endothelium triggers the production or upregulation of
several molecules promoting leukocyte recruitment: a) endothelial cells secrete a variety of
chemokines, which are deposited on their apical surface and induce ‘inside-out’ signalling
leukocyte integrin activation, and b) they induce or upregulate cell adhesion molecules on
their luminal cell surface, which function as counter-receptors of integrins on leukocytes,
thereby mediating leukocyte adhesion (reviewed in Ley et al., 2007; Chavakis et al., 2009;
Chavakis, 2012).

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Chemokines act via their G-protein-coupled receptors and induce signalling cascades called
‘inside-out’ signalling, which lead to the activation of the extracellular domains of integrins
(reviewed in Chavakis et al., 2009; Ley et al., 2007). Chemokine-induced inside-out
signalling comprises several inter-dependent pathways, including a) activation of
phospholipase C, which leads to intracellular Ca2+ flux from the endoplasmatic reticulum
and generation of inositol-1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG) (Zarbock et
al., 2011), b) activation of small GTPases, such as Rap1 (RAS-related protein 1) by guaninenucleotide-exchange factors (Shimonaka et al., 2003; Lafuente and Boussiotis, 2006;
Chavakis et al., 2009; Gahmberg et al., 2009) and c) interaction of intracellular proteins,
such as talin-1, kindlin-3, cytohesin-1 and 14-3-3-family members, with the cytoplasmic tail
of integrins. The binding of the latter proteins to the ! subunit of e.g. LFA-1 results in
separation of the two cytoplasmic tails thereby inducing and sustaining the conformational
changes in the extracellular domain (reviewed in Alon and Feigelson, 2012, Hogg et al.,
2011; Moser et al, 2009; Choi et al., 2008a; Chavakis et al., 2009; Kinashi, 2005; Fagerholm
et al., 2002; Kolanus et al, 1996; Gahmberg et al., 2009). Besides chemokines and PSGL-1ligation, Toll-like receptors also induce integrin activation (Harokopakis et al., 2006;
Harokopakis and Hajishengallis, 2005). Recently, Toll like receptor 2 (TLR2)- and Toll like
receptor 5 (TLR5)-ligation was shown to rapidly activate integrin-dependent leukocyte
adhesion to immobilized intercellular cell-adhesion molecule 1 (ICAM-1) or fibronectin
through activation of a pathway requiring Rac1, NADPH oxidase 2-mediated reactive
oxygen species production and activation of Rap1-GTPase (Chung et al, 2014).
Furthermore, TLRs activate via Ras the PI3K isoform p100#, which then promotes
activation of the "4!1-integrin (Schmid et al., 2011). The distinct triggering signals and
pathways involved in ‘inside-out’ signalling ensure a great diversity in integrin activation
and thereby stimulation of inflammatory cell recruitment under different inflammatory
conditions (Hyduk et al., 2007; Kinashi, 2005; Lafuente and Boussiotis, 2006; Shamri et al.,
2005; Wegener et al., 2007 and reviewed in Chavakis et al., 2009; Hogg et al., 2011; Ley et
al., 2007).
Pharmacol Ther. Author manuscript; available in PMC 2016 March 01.
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Upon activation, integrins bind to their ligands, mediating slow rolling, leukocyte adhesion
and crawling and participate in transendothelial migration (Ley et al., 2007). Moreover,
leukocyte integrins may participate in other functions such as immune synapse formation or
phagocytosis (Dupuy and Caron, 2008; Springer and Dustin, 2012). Integrin activation
cooperates with selectins to mediate slow rolling. LFA-1 or Mac-1-deficient mice both show
significantly increased leukocyte rolling velocities under inflammatory conditions,
indicating that !2-integrins contribute to “slowing-down” of rolling neutrophils (Dunne et
al., 2002).
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VLA-4 binds to the vascular cell-adhesion molecule (VCAM)-1 and autotaxin (Kanda et al.,
2008; Gahmberg et al., 2009), while LFA-1 and Mac-1 interact with ICAM-1 and ICAM-2
(reviewed in Springer, 1994; Chavakis, 2012; Chavakis et al., 2009; Gahmberg et al., 2009).
Mac-1 is a very promiscuous receptor interacting with numerous other ligands. For instance,
it binds to iC3b, thereby promoting complement-dependent phagocytosis by macrophages
(Micklem and Sim, 1985; Dupuy and Caron, 2008). Mac-1 also interacts with fibrinogen
(Altieri et al., 1990), which was shown to be of importance for bacterial elimination by
leukocytes (Flick et al., 2004). Furthermore it binds heparin (Diamond et al., 1995), elastase
(Cai and Wright, 1996) and other proteolytic enzymes, such as kininogen components,
plasminogen, fragments thereof, urokinase or its receptor (Chavakis et al., 1999; Chavakis et
al., 2001; Chavakis et al., 2005; Pluskota et al., 2003, Wei et al, 1996; Simon et al., 1996),
thereby orchestrating cell surface-associated proteolytic activity. Mac-1 was also
demonstrated to interact with the receptor for advanced glycation end products (RAGE)
(Orlova et al., 2007; Chavakis et al., 2003a; Frommhold et al., 2010), an interaction that
could be relevant in diabetes-associated vascular inflammation (Yamamoto and Yamamoto,
2013). It also interacts with membrane glycoprotein GPIb" (Ehlers et al., 2003; Chavakis et
al., 2003b; Simon et al., 2000) and Junctional Adhesion Molecule-C (JAM-C) on platelets
(Santoso et al., 2002), thereby mediating leukocyte-platelet interactions. Finally, "4!7 on
lymphocytes interacts with the mucosal vascular addressin cell-adhesion molecule 1
(MAdCAM1) (Berlin et al., 1993; and reviewed in Springer, 1994; Ley et al., 2007;
Chavakis et al., 2009).
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Leukocyte-platelet cross-talks play also an important role in promoting leukocyte adhesion
and leukocyte recruitment (Langer and Chavakis, 2009). Upon vascular injury, platelets
adhere to the vascular endothelium where they stimulate leukocytes indirectly by the release
of chemokines and inflammatory cytokines (von Hundelshausen and Weber, 2007; Zarbock
et al., 2007b), as well as directly through cell-to-cell contact (Zarbock et al., 2007b). For
instance, platelets secrete CC-chemokine ligand 5 (CCL5 or RANTES), CXC-chemokine
ligand 4 (CXCL4) and CXCL5, thereby triggering monocyte arrest (Huo et al., 2003).
Furthermore, platelet P-selectin interacts with PSGL-1 on leukocytes (Moore et al., 1992;
Larsen et al., 1989), while GPIb, JAM-C and platelet-associated fibrinogen all bind to
leukocyte Mac-1 (Ehlers et al., 2003; Santoso et al., 2002; Weber and Springer, 1997).
These interactions contribute to the formation of direct platelet-leukocyte cell-to-cell
interactions (Massberg et al., 2002; Massberg et al., 2005; Burger and Wagner, 2003;
Zarbock, 2007b; Santoso et al., 2002; Simon et al., 2000). The significance of leukocyteplatelet interactions in vascular inflammation is evidenced by their critical role in the
formation of atherosclerotic lesions (Massberg et al., 2002; Huo et al., 2003).
Pharmacol Ther. Author manuscript; available in PMC 2016 March 01.
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Ligand binding of integrins triggers signalling pathways designated ‘outside-in signalling’,
which lead to strengthening of leukocyte adhesion and subsequent spreading. Ligation of !2integrin induces the activation of the Src proteins Hck and Fgr (Giagulli et al., 2006) and
phosphorylation of spleen tyrosine kinase (Mocsai et al., 2006; reviewed in Hogg et al.,
2011). In T cells, proteins involved in outside-in signalling are the Lck and $-chainassociated protein kinase of 70kDa (Evans et al., 2011). During this step, integrins associate
intracellulary with cytoskeletal proteins; for instance "4!1-integrin interacts with paxillin
(Liu et al., 1999), which contributes to the stability of activated integrin conformation
(Goldfinger et al., 2003; Kinbara et al., 2003). Moreover leukocyte integrins associate with
further cytoskeletal proteins, such as vinculin or actinin (Mace et al., 2010; Stanley et al.,
2008); this association facilitates formation of focal adhesions and further integrindependent steps (Kinbara et al., 2003). Following firm arrest, leukocytes crawl on the
endothelial cell surface in a manner dependent on !2-integrins, a process also named
locomotion (Schenkel et al., 2004; Phillipson et al, 2006) that allows leukocytes to identify
an appropriate site to migrate through the endothelial cell monolayer.
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Transmigration through venular walls is the final step in the process of leukocyte emigration
into inflamed tissues. Leukocytes mainly transmigrate paracellularly at interendothelial
junctions, although transcellular migration through the endothelial cell body also rarely
takes place (Nourshargh et al., 2010; Woodfin et al., 2011; Choi et al., 2009).
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The critical role of LFA-1 and Mac-1 during transmigration has long been established
(Smith et al., 1989; Henderson et al., 2001). Shaw et al. have shown that the distribution of
LFA-1 in transmigrating neutrophils rapidly changes to form a ring-like cluster at the
neutrophil-endothelial junctions, while endothelial ICAM-1 co-localizes with LFA-1 in
these clusters (Shaw et al., 2004). ICAM-2 also mediates neutrophil transmigration, due to
its interaction with Mac-1 and LFA-1 (Staunton et al., 1989; Xie et al., 1995), as shown by
genetic or antibody-mediated inactivation of ICAM-2 (Huang et al., 2006). Furthermore,
there is ample evidence that integrins interact with JAM proteins in the process of
transmigration. LFA-1 was shown to bind to JAM-A, while Mac-1 interacts with JAM-C;
these interactions may promote leukocyte diapedesis (Chavakis et al., 2004; Lamagna et al.,
2005; Keiper et al., 2005; Orlova and Chavakis, 2007; Ostermann et al., 2002). The
important role of JAM-C in leukocyte transmigration in vivo has been shown in a study by
Woodfin et al., linking the reverse transendothelial migration with reduced expression of
JAM-C at the endothelial cell junctions (Woodfin et al., 2011). Furthermore, JAM-A was
recently demonstrated to promote monocyte recruitment to the arterial wall during
atherosclerosis (Schmitt et al., 2014).
Numerous other endothelial molecules, primarily located at junctions, such as platelet/
endothelial-cell adhesion molecule 1 (PECAM-1, CD31), CD99 and endothelial cell
selective adhesion molecule are also involved in leukocyte transmigration (Ley et al., 2007;
Nourshargh et al., 2010; Muller, 2003; Muller, 2014; Schenkel et al., 2002; Wegmann et al.,
2006). Interestingly, ICAM-2, JAM-A and PECAM-1 play a rather sequential role during
leukocyte transmigration (Woodfin et al., 2009). Endothelial PECAM-1 promotes leukocyte
transmigration by undergoing homophilic interactions with PECAM-1 on monocytes
(Mamdouh et al., 2003; Muller et al., 2003), through which it can up-regulate "6!1-integrin
Pharmacol Ther. Author manuscript; available in PMC 2016 March 01.
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(Dangerfield et al., 2002); in addition, PECAM-1 also undergoes a heterophilic interaction
with CD177, which may contribute to transmigration (Sachs et al., 2007).
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CD99 through homophilic interactions (Muller et al., 2003 Schenkel et al., 2002) and
CD99L2 (Bixel et al., 2010), also promote leukocyte transmigration (Schenkel et al., 2002;
Bixel et al., 2004; Bixel, 2010). Finally, VE-cadherin, the most important gatekeeper of
vascular endothelial integrity may be transiently distributed away from the junctional
regions during diapedesis thus permitting trans-endothelial leukocyte migration, whereas
phosphorylation of VE-cadherin also plays a regulatory role in the process of diapedesis
(Shaw et al., 2001; Vestweber et al., 2009; Wessel et al., 2014).

Leukocyte integrins as targets in inflammatory disease models
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Leukocyte recruitment into an inflamed tissue is a cardinal hallmark in several inflammatory
diseases. Infiltrating leukocytes induce, promote and perpetuate inflammation, whereas their
clearance is critical for the resolution of the inflammatory process. Due to their critical role
in leukocyte recruitment, leukocyte integrins have emerged as therapeutic targets in several
inflammatory diseases (Yonekawa and Harlan, 2005). In the following section, we review
the importance of leukocyte integrins in different animal models of inflammatory disorders,
in which integrin targeting has been proven to be beneficial (Figure 2).
Multiple sclerosis
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Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS)
characterized by demyelination. The clinical course ranges from relapsing-remitting to
progressive forms and can lead to severe disability and mortality (Bhat and Steinman, 2009;
Confavreux et al., 2000; Confavreux and Vukusic, 2006; Lassmann et al., 2012). The rodent
model of MS is experimental autoimmune encephalomyelitis (EAE); pathology in this
model (and most likely in MS as well) is triggered by infiltration of autoreactive T cells,
which are targeted against antigens of the myelin sheath through the blood-brain barrier
(BBB) into CNS. This initiates a strong neuroinflammatory response, involving BBB
disruption (Minagar and Alexander, 2003) and recruitment of further immune cells (Bhat
and Steinman, 2009; Korn, 2008). Thus, leukocyte recruitment is a critical event in the
pathogenesis of EAE and MS (Goverman, 2009; Popescu and Lucchinetti, 2012; Simmons
et al., 2013).
The role of "4!1-integrin in leukocyte recruitment to the inflamed CNS in the course of
EAE has been extensively investigated (Sheremata et al., 2005). The identification of this
integrin as a major player in EAE and MS resulted in the development of natalizumab, a
monoclonal antibody against "4, which has been approved for the treatment of patients with
MS (Weinstock-Guttman, 2013). Initial studies demonstrated that leukocyte adherence to
the inflamed endothelium in the CNS was mediated by the "4!1-integrin / VCAM-1
interaction; consistently, blockade of "4!1-integrin prevented disease development in rats
(Yednock et al., 1992) and mice (Baron et al., 1993). By using a model of adoptive transfer
in EAE, Baron et al. further demonstrated that only antigen-specific T cells expressing
"4!1-integrin were able to migrate into the brain parenchyma and that blocking "4-integrin
with antibodies preferentially inhibited the recruitment of these cells to the inflamed CNS
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(Baron et al., 1993). The effect of "4 antibodies was mediated by blockade of "4!1- rather
than "4!7-integrin, as clarified by inhibition studies with antibodies against "4!7
heterodimer or !7-integrin (Engelhardt et al., 1998), whereas endothelial overexpression of
the "4!7-integrin counter-receptor MAdCAM-1 did not affect EAE severity (Döring et al.,
2011). Intravital microscopy approaches underlined the importance of "4-integrin and its
collaboration with P-selectin for the adhesion of leukocytes to the brain endothelium
(Kerfoot and Kubes, 2002). Additional in vitro and in vivo studies, using intravital
microscopy, further supported the involvement of "4!1-integrin binding to VCAM-1 in the
adhesion of T cells to the vasculature of the white matter (Laschinger and Engelhardt, 2000;
Vajkoczy et al., 2001). Blocking of "4!1-integrin with natalizumab was shown to inhibit
firm adhesion of human T cells to the inflamed BBB in mice with EAE, without affecting
the rolling or initial contact of these cells (Coisne et al., 2009). Moreover, "4!1-integrin was
shown to mediate initial recruitment of encephalitogenic T cells as well as the secondary
infiltration of inflammatory cells, thereby being involved in initiating and sustaining CNS
inflammation (Brocke et al., 1999). Experiments with cell-specific deletion of !1-integrin
demonstrated that T cells, rather than myeloid cells, were dependent on "4!1-integrin for
their migration to the inflamed CNS, supporting the notion that the therapeutic effect of
antibodies against "4 is largely mediated by the inhibition of T cell extravasation (Bauer et
al., 2009). However, "4!1-integrin is involved in the recruitment of additional immune cells
in the inflamed CNS, including immature DCs (Jain et al., 2010) and Natural Killer (NK)
cells (Gan et al., 2012). The different observations from rodent EAE establishing a major
role for "4!1-integrin in disease pathogenesis resulted in the clinical use of "4!1-integrin
inhibition as a therapeutic principle in MS, which will discussed in the following section.
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Several studies investigated whether inhibition of !2-integrins or their ligands could be of
potential benefit in EAE and MS. Using antibodies against CD11a and CD11b, Gordon et al.
demonstrated that targeting these !2-integrins could block or delay the onset of EAE
(Gordon et al., 1995). Dugger et al. performed transfer of CD11a−/− T cells to wild type
mice and demonstrated that these cells, even though they infiltrate lymph nodes and CNS,
caused less severe disease than wild-type controls. On the other hand, transfer of wild type
encephalitogenic T cells to CD11a−/− mice worsened the outcome of EAE, thereby
indicating that CD11a may have both effector and suppressor functions in EAE pathogenesis
(Dugger et al., 2009). Specifically, these seemingly contradictory findings could be
attributed to the fact that LFA-1 is involved in different functions besides T cell trafficking,
including functioning as a co-stimulatory molecule (Van Seventer et al., 1991) or as a
molecule that regulates the function of regulatory T cells (Treg) (Tran et al., 2009). For
instance, LFA-1 deficiency resulted in an altered balance between effector T cells and Tregs
in favor of the former, which led to increased severity of EAE in CD11a-deficient mice
(Gültner et al., 2010). Based on the fact that both Th1 lymphocytes and Th17 lymphocytes
contribute to EAE development (Jäger et al., 2009; Kebir et al., 2007; Kleinschek et al.,
2007), the involvement of LFA-1 in the recruitment of these separate lymphocyte
populations into the CNS was addressed. The infiltration of lymphocytes to the draining
lymph node following immunization as well as the development of Th17 cells were
significantly impaired in LFA-1−/− mice, thereby resulting in reduced disease severity
(Wang et al., 2007). Rothhammer et al. further demonstrated that LFA-1 is also important
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for Th17 trafficking to the inflamed CNS. In this study, it was reported that Th1 and Th17
cells engage different integrins for their migration to the CNS. Blockade of "4-integrin
protected from EAE induced by adoptive transfer of Th1 but not of Th17 lymphocytes. The
latter entered the CNS in an "4 integrin-independent manner. In contrast, the infiltration of
Th17 cells into the brain parenchyma was mediated by LFA-1. Thus, Th17 cell migration to
the CNS requires LFA-1, whereas Th1 cells preferentially use "4-integrin for this process
(Rothhammer et al., 2011, Glatigny et al., 2011). With regards to the role of LFA-1 in the
migration of T lymphocytes across the BBB, Laschinger et al. demonstrated that LFA-1
participates in the transendothelial migration but not in endothelial adhesion (Laschinger et
al., 2002). The effect of inhibiting the LFA-1 ligand ICAM-1 in the course of EAE was also
studied. Even though studies using inhibitory antibodies against ICAM-1 have shown
contradictory results (Archelos et al., 1993; Morrissey et al., 1996; Willenborg et al., 1993),
EAE development was significantly attenuated in ICAM-1−/− mice (Bullard et al, 2007b), as
well as by targeting ICAM-1 with a staphylococcal-derived anti-adhesive protein (Xie et al.,
2006). Besides CD11a, deficiency of CD11b (Bullard et al., 2005) or CD11c (Bullard et al.,
2007a) has also been demonstrated to ameliorate development of EAE. Moreover, the
CD11b-mediated interaction of leukocytes with platelets contributes to inflammatory cell
recruitment to the CNS in the course of EAE pathogenesis. Inhibition of the leukocyteplatelet interaction by blocking the binding of Mac-1 to platelet GPIb resulted in significant
amelioration of disease severity (Langer et al., 2012).
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Psoriasis

NIH-PA Author Manuscript

Psoriasis is a chronic inflammatory disease of the skin, which is characterized by
erythematous scales; recent evidence has suggested an important role of IL-17 derived from
different cells as a pathogenic component in psoriasis (Krueger et al., 2012; Leonardi et al.,
2012; Martin et al., 2013; Pantelyushin et al., 2012). Th1, Th17 cells, #% T cells, innate
lymphocytes and DCs are abundant inflammatory cell populations in psoriatic lesions
(Chamian and Krueger, 2004; Chamian et al., 2005; Lowes et al., 2008; Pantelyushin et al.,
2012). Treatment of patients with efalizumab, a monoclonal antibody that targets CD11a
resulted in significant reduction of TNF and iNOS-expression and of DC numbers in lesions
(Lowes et al., 2005). In a psoriatic model engaging human skin-SCID (severe combined
immunodeficiency) mouse chimeras, treatment with efalizumab limited skin inflammation
in the transplant (Zeigler et al., 2001; Stenderup et al., 2011). Besides LFA-1 blockade,
Schön et al. demonstrated that Mac-1 blockade ameliorates skin manifestations in the flaky
skin mice (fsn−/− mice) that develop psoriasiform skin lesions. Histological analysis
revealed that treatment with an antibody against CD11b resulted in decreased neutrophil and
T cell infiltration. This finding implies Mac-1 on neutrophils in the inflammatory process
that characterizes at least this model of psoriasis (Schön et al., 2000). The effect of Mac-1
blockade was also confirmed in another murine model of experimental psoriasiform
dermatitis (Leon et al., 2006). One of the Mac-1 counter-receptors on the endothelium is
RAGE (Chavakis et al., 2003a; Orlova et al., 2007; Frommhold et al., 2010). Interestingly,
RAGE serves also as the receptor for S100A7, also designated psoriasin, which is
overespressed in psoriatic lesions and exerts a strong chemotactic activity for neutrophils
(Wolf et al., 2008; Wolf et al., 2010). Whether blockade of the interaction of RAGE with its
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counter-receptor Mac-1, or its S100 ligands could be therapeutically relevant in psoriasis is
worth assessing.
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In addition to !2-integrins LFA-1 and Mac-1, blocking of "1!1-integrin (VLA-1), which
serves as a collagen receptor, inhibited the infiltration of epidermal T cells in a
xenotransplantation psoriasis model. This study, moreover, established that the presence of
"1!1-integrin in epidermal effector T cells was associated with the expression of high levels
of interferon-#. Thus, "1!1-integrin may represent a potential therapeutic target in psoriasis
(Conrad et al., 2007).
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Interestingly the !2-integrin was demonstrated to play a regulatory role in the development
of psoriasis as well. Mice bearing a hypomorphic CD18 mutation (CD18hypoPL/J mice),
resulting in decreased CD18 expression, develop psoriasiform dermatitis (Peters et al.,
2006), featured by increased accumulation of CD4+ and #% T cells (Gatzka et al., 2013) and
decreased presence of regulatory T cells (Singh et al., 2013) at the skin lesions. !2-integrin
deficiency has been previously associated with dysregulation of IL-17 production, due to
defective neutrophil recruitment to peripheral tissues and subsequently reduced clearance of
apoptotic neutrophils by macrophages (Stark et al., 2005; Moutsopoulos et al., 2014), as
discussed in the following section. The resulting reduction of IL-23 production by
macrophages leads to #% T cell activation, which then produce IL-17 (Stark et al., 2005).
This mechanism could be a possible explanation for the aforementioned findings in mice
with decreased CD18 expression.
Inflammatory bone loss
Inflammatory cell recruitment is a common denominator of several disorders involving bone
loss, with rheumatoid arthritis (RA) being the most prominent one. Synovial inflammation
in RA results from infiltrating neutrophils, T cells, B cells, plasma cells, DCs and
macrophages. Inflammatory cells together with osteoclasts present in the synovial
membrane act synergistically in the destruction of the adjacent bone (Choy, 2012).
Presentation of arthritis-specific antigens by DCs, macrophages and B cells to CD4+ T cells
is considered an important trigger in disease development (Choy, 2012).
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The role of leukocyte integrins in RA has been addressed in several animal models. In the
rat model of adjuvant arthritis, T cell infiltration was shown to be independent of the !2integrins LFA-1 and Mac-1, whereas a partial inhibition of neutrophil recruitment was
observed when LFA-1 was inhibited. However, upon concomitant blockade of both LFA-1
and Mac-1, neutrophil recruitment was abolished (Issekutz and Issekutz, 1993). In the same
model, T cell recruitment was shown to depend on "4!1-integrin (Issekutz and Issekutz,
1991); this integrin mediated infiltration of adoptively transferred arthritogenic T cells to the
synovium (Issekutz et al., 2003). Furthermore, combined blockade of LFA-1 and VLA-4integrins was required for the complete inhibition of monocyte infiltration (Issekutz and
Issekutz, 1995).
The involvement of !2-integrins in the development of murine arthritis was studied in the
model of K/B xN serum transfer arthritis. Watts et al. demonstrated that mice deficient in
the common !2 subunit were protected from arthritis development. Additionally, CD11a

Pharmacol Ther. Author manuscript; available in PMC 2016 March 01.

Mitroulis et al.

Page 11

NIH-PA Author Manuscript

deficient mice did not develop arthritis, whereas no effect was observed in CD11b deficient
mice, suggesting that LFA-1 but not Mac-1 contributes to disease induction. LFA-1 was
required not only for arthritis development but also for maintenance of synovial
inflammation, as shown by disease amelioration after administration of anti-LFA-1 antibody
in mice with already established arthritis, thereby suggesting a therapeutic potential for
LFA-1 targeting in RA (Watts et al., 2005).
LFA-1 is also involved in bone loss in the context of inflammatory arthritis. Barck et al.
studied the effect of LFA-1 blockade in the formation of bone erosions in the murine model
of collagen induced arthritis. Using 3-dimensional micro-CT of mouse paws to evaluate
joint cortical bone volume, they demonstrated that treatment with anti-LFA-1 antibody
ameliorated both the clinical course and the radiographic findings (Barck et al., 2004).
Furthermore, "2!1 integrin, a receptor for collagen type I, was shown to promote arthritis in
the antigen-induced arthritis (AIA) and the human TNF-transgenic mouse model. Mice
deficient in "2!1 showed reduced cartilage erosions and joint pathology, as compared to
wild-type mice (Peters et al., 2012).

NIH-PA Author Manuscript

A link between inflammatory bone loss and LFA-1 has been recently demonstrated in
periodontitis. LFA-1 deficiency was associated with severe periodontal bone loss and lack of
neutrophil recruitment in the periodontal tissue in both mice and men with type I leukocyte
adhesion deficiency (LAD-I). This was attributed to dysregulated overproduction of IL-17
as a result of a defective “neutrostat”-feedback mechanism in mice and individuals with
defective leukocyte recruitment (Moutsopoulos et al., 2014). Specifically, when neutrophils
cannot transmigrate to peripheral tissues (as occurs in LAD-I), the inhibitory signals for
IL-23 expression by phagocytes (normally associated with apoptotic cell efferocytosis) are
abrogated leading to T cell overexpression of IL-17. IL-17 in turn promotes granulopoiesis
through G-CSF, consistent with blood neutrophilia in LAD-I patients and relevant mouse
models (Stark et al., 2005). Interestingly, topical inhibition of IL-17 blocked inflammatory
bone loss in mouse models mimicking LAD-I-associated periodontitis (Moutsopoulos et al.,
2014).
Inflammatory bowel disease
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Inflammatory bowel diseases (IBD), namely Crohn’s disease (CD) and ulcerative colitis
(UC), are chronic disorders of the gastrointestinal tract. Advances in the understanding of
the pathogenesis of intestinal inflammation enabled the development of specific therapies,
with monoclonal antibodies e.g. targeting TNF (Kontoyiannis et al., 2002; Dassopoulos et
al., 2013).
Studies with animal models of IBD revealed the critical involvement of leukocyte integrins
in intestinal inflammation, which enabled the development of targeted therapies for the
treatment of CD and UC, as discussed below. Early studies demonstrated the central role of
!7-integrins for the formation of gut-associated lymphoid tissue (GALT), which includes
Peyer’s patches, lamina propria lymphocytes and intra-epithelial lymphocytes of the
intestine (Koboziev et al., 2010; Gorfu et al., 2009). Mice deficient in the !7-integrin subunit
have hypoplastic GALT, which was further attributed to defective T cell recruitment
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(Wagner et al., 1996). Furthermore, antibodies targeting "4 integrin, an epitope present on
the "4!7-integrin or the !7 subunit significantly attenuated T cell homing to Peyer’s patches,
without affecting homing to peripheral lymph nodes. In the same study, it was also shown
that the mucosal addressin MAdCAM-1 mediates T cell infiltration in mucosal lymphoid
tissue (Hamann et al., 1994). Using !7−/− mice, Kunkel et al. confirmed the involvement of
!7-integrin in adhesion of leukocytes to Peyer’s patch endothelial venules (Kunkel et al.,
1998). Treatment with anti-!7 and anti-MAdCAM-1 antibodies was shown to ameliorate
experimental murine chronic colitis, by affecting T cell recruitment to the colonic mucosa
and mesenteric lymph nodes (Picarella et al., 1997). The involvement of !7-integrins in the
development of mouse colitis was also shown in the SAMP1/YitFc model of inflammatory
Crohn’s disease-like ileitis. In this model, !7-integrin blockade was efficient to significantly
suppress inflammation, only when combined with L-selectin inhibition (Rivera-Nieves et al.,
2005). In the same model, !7-integrin deficiency ameliorated colitis by inhibiting B cell
homing to mesenteric lymph nodes on top of blocking T cell infiltration (Gorfu et al., 2010).
Inhibition of "E!7-integrin reduced mucosal inflammation in IL-2−/− mice immunized with
TNP-OVA, even when mice were treated after the establishment of colitis (Ludviksson et
al., 1999). However, !7-deficiency in mice did not significantly ameliorate colitis course
(Sydora et al., 2002). On the other hand, Apostolaki et al. have shown the dependency of T
cell recruitment to intestinal mucosa on !7-integrins in a TNF-dependent model of Crohn’s
disease; moreover, !7-deficiency completely abrogated colitis development (Apostolaki et
al., 2008). Furthermore, a recent study by Villablanca et al. demonstrated that mice deficient
in !7-integrin in the innate immune compartment show increased susceptibility to T cell
mediated colitis. The authors proposed that the reduced migration of !7-deficient tolerogenic
mononuclear phagocytes into gut mucosa contributes to this phenotype (Villablanca et al.,
2014).
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Several studies suggested a role of !2-integrins in experimental colitis. In the rat model of
2,4,6-trinitrobenzene sulfonic acid-induced colitis, administration of antibodies against
Mac-1 resulted in significant inhibition of inflammatory cell recruitment, which was
associated with a decreased mucosal damage (Palmen et al., 1995). By transferring
CD11a−/− CD4+CD25− T cells to RAG−/− recipients, Pavlick et al. demonstrated that
expression of LFA-1 on T cells is required for disease induction and for the infiltration of
CD4+ T cells to mesenteric lymph nodes and to intestinal lamina propria (Pavlick et al.,
2006). Using the same approach CD18 on T cells was identified to promote colitis induction
(Ostanin et al., 2007).
The identified role of leukocyte integrins in models of IBD paved the way for the
development of targeted therapeutic agents, as discussed in the following section.

Leukocyte integrin blockade in clinical use
As a result of the large body of evidence regarding the central role of leukocyte integrins in
animal models of inflammatory diseases, different leukocyte integrin targeting strategies
have reached clinical use (Yonekawa and Harlan, 2005) (Table 1).
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Efalizumab (Raptiva, anti-CD11a, Genentech) is a humanized monoclonal IgG1 antibody
that is directed against the alpha chain (CD11a) of the !2-integrin LFA-1, that blocks the
interaction between leukocyte LFA-1 and ICAM-1 (Dedrick et al., 2002). Phase III clinical
trials demonstrated that efalizumab administration results in the amelioration of
dermatologic features of psoriasis (Gordon et al., 2003; Lebwohl et al., 2003, Leonardi et al.,
2005), which can be attributed to reduction of inflammatory cell recruitment and reversal of
keratinocyte hyperplasia at psoriatic lesions (Reich et al., 2012; Gottlieb et al., 2002).
Despite having beneficial effect on the skin manifestations, it was not effective in the
treatment of psoriatic arthritis (Papp et al., 2007), while several reports suggest that
treatment with efalizumab might even result in new-onset severe arthritis (Viguier et al.,
2008; Myers et al., 2006). Despite its effectiveness, it was withdrawn in 2009 due to the
high risk of John Cunningham (JC) polyomavirus reactivation and development of
progressive multifocal leukoencephalopathy (PML) in patients under long-term efalizumab
administration (Weger, 2010).
Alpha4-integrins
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Natalizumab (Antegren, Tysabri; Elan Pharma Ltd., Letchworth, UK and Biogen-Idec,
Durham, NC, USA) is a recombinant humanised monoclonal IgG4 antibody against the "4integrin subunit, blocking both "4!1- and "4!7-integrins. It prevents the migration of
leukocytes across the blood–brain barrier into the CNS by blocking the interaction between
"4!1-integrin and VCAM-1 (Rudick and Sandrock, 2004; Ransohoff, 2007; Rudick et al.,
2013); moreover, it inhibits the interaction of "4!7-integrin with endothelial MAdCAM-1
and thereby homing of lymphocytes to gastrointestinal lymphoid tissue (Hamann et al.,
1994). Studies in patients with MS have shown that natalizumab administration significantly
reduced the numbers of total leukocytes, CD4+ T cells, CD8+ T cells, B cells and plasma
cells in the cerebrospinal fluid (Stüve et al., 2006). A significant reduction in the number of
CD209+ antigen presenting DCs in cerebral perivascular spaces and decreased expression of
major histocompatibility complex class II was also observed in brain autopsies from a
patient with PML that had received natalizumab (del Pilar Martin et al., 2008). These effects
are localized to the CNS, as natalizumab did not reduce the numbers of CD4+ and CD8+ T
cells in the periphery (Kivisäkk et al., 2009).

NIH-PA Author Manuscript

After successfully completing phase III clinical trials (Polman et al., 2006, Rudick et al.,
2006), natalizumab was approved as the first targeted therapy for the treatment of relapsingremitting multiple sclerosis. Natalizumab is associated with increased risk for reactivation of
latent JC virus infection and development of PML (Bloomgren et al., 2012); however, a
recently published study confirmed the beneficial role of natalizumab in stabilizing disease
activity and diminishing the risk of relapses in patients with relapsingremitting multiple
sclerosis (O’Connor et al., 2014). Phase II and III studies have also shown that natalizumab
is effective as an induction and maintenance therapy in patients with Crohn’s disease (Ghosh
et al., 2003; Sandborn et al., 2005; Targan et al., 2007). However, due to the risk for PML
development it is approved in the United States under a restricted distribution program
(Chen et al., 2013).
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Furthermore, antibodies targeting the interaction between "4!7-integrin and MAdCAM
have been developed. Vedolizumab and etrolizumab target "4!7-integrin, whereas
PF-00547659 targets MAdCAM (Bamias et al, 2013). The selective blockade of "4!7integrin leaving "4!1 unaffected should minimize the risks associated with the inhibition of
leukocyte recruitment to the CNS. Vedolizumab (Millennium Pharmaceuticals) is a
humanized IgG1 monoclonal antibody that is effective as an induction and maintenance
therapy for moderate to severe UC and Crohn’s disease, as well as in patients with moderate
to severe Crohn’s disease that did not previously respond to other treatments (Feagan et al.,
2013; Sandborn et al., 2013; Sands et al., 2014). Vedolizumab was recently approved by the
FDA for the treatment of Crohn’s disease.
Etrolizumab is a humanised monoclonal antibody that selectively binds the !7-subunit of
both the "4!7 and "E!7-integrin heterodimers, antagonizing both "4!7-MAdCAM-1mediated lymphocyte recruitment and the "E!7-E-cadherin interaction (Lin and Mahadevan,
2014), which mediates adhesion of "E!7 T cells to epithelial cells (Cepek et al, 1993;
Hadley and Higgins, 2014). In a recently published phase II clinical trial, etrolizumab was
shown to have a beneficial effect as an induction therapy in the treatment of patients with
moderate to severe IBD (Vermeire et al., 2014).
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Despite the high efficacy of integrin-targeted therapies in inflammatory diseases, the
relatively frequent occurrence of severe adverse events precludes the administration of such
agents to a wider spectrum of patients with inflammatory diseases.

Endogenous inhibitors of leukocyte recruitment
Besides the aforementioned antibodies and inhibitors that have been developed to
therapeutically target integrins and block leukocyte recruitment, the recent discovery of
endogenous negative regulators of the leukocyte adhesion cascade may pave the way for the
development of novel, more efficient strategies to therapeutically target leukocyte adhesion
in inflammatory and autoimmune pathologies (Chavakis, 2012; Hajishengallis and
Chavakis, 2013). We will therefore summarize here recent knowledge on endogenous
inhibitors of leukocyte recruitment with a special focus on the integrin inhibitor
Developmental endothelial locus-1 (Del-1).
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Del-1: an endogenous anti-inflammatory factor blocking leukocyte !2-integrins
Del-1, also designated epidermal growth factor (EGF)-like repeats and discoidin-I-like
domains 3 (EDIL3) is a glycoprotein with three EGF-like repeats and two C-terminal
discoidin I-like domains; the latter can interact with phosphatidylserine and phospholipids
(Dasgupta et al., 2012; Chavakis et al., 2009). It is expressed and secreted by endothelial
cells and can associate with the extracellular matrix as well as the endothelial cell surface
(Chavakis et al., 2009). Association with the endothelial cell surface is mediated by binding
to surface proteoglycans or to integrin "v!3 by means of an Arg–Gly–Asp motif on the
second EGF-like repeat (Chavakis et al., 2009; Hidai et al., 2007). Although expressed by
endothelial cells, it is not present in all tissues and organs. Its expression is highest in the
brain, followed by the lung, the adrenal or the gingiva, whereas it is hardly expressed in the
liver, thereby pointing to the diversity and heterogeneity of the endothelium of different
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tissues / organs (Choi et al., 2008b; Kanczkowski et al., 2013). We identified Del-1 to act as
a negative regulator of the leukocyte integrin LFA-1. Del-1 binds to LFA-1 integrin and
antagonizes binding of the latter to ICAM-1, thereby blocking LFA-1-dependent leukocyte
adhesion onto the vascular endothelium (Choi et al., 2008b). Besides LFA-1, Del-1 was
recently shown to interact with Mac-1 as well, thereby blocking the binding of Mac-1 with
complement component iC3b. This results in a Del-1-mediated inhibition of complement/
Mac-1-dependent phagocytosis, an action that could also contribute to the anti-inflammatory
functions of Del-1 (Mitroulis et al., 2014). The role of Del-1 as a negative regulator of
leukocyte recruitment stands in keeping with its highest expression levels in immune
privileged organs, such as the brain or the eye. Del-1-deficient mice displayed elevated
LFA-1-dependent neutrophil recruitment in LPS-induced acute lung injury and in the dorsal
skinfold chamber model. Injection of soluble Del-1 could ameliorate inflammatory cell
recruitment to the lung or the peritoneum in acute models of inflammation (Choi et al.,
2008b). Additionally, Del-1-deficiency was recently shown to enhance bleomycin-induced
lung fibrosis (Kang et al., 2014) and systemic inflammation-related adrenal dysfunction
(Kanczkowski et al., 2013). Thus, Del-1 might represent an interesting novel approach for
the treatment of inflammatory lung diseases.
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Interestingly, Del-1 expression in endothelial cells is down-regulated by inflammatory
factors, such as LPS, TNF or IL-17A but not IL-17F (Choi et al., 2008b; Eskan et al., 2012;
Shin et al., 2013), which suggests that inflammatory stimuli do not only elevate expression
of integrin ligands ICAM-1 and VCAM-1 on the endothelium, but at the same time reduce
the levels of the integrin inhibitor Del-1; both actions function synergistically to promote
leukocyte adhesion. The IL-17-mediated down-regulation of endothelial Del-1 expression
promoted neutrophil recruitment and inflammatory bone loss in the context of periodontitis,
which is a chronic neutrophil-dependent disease (Eskan et al., 2012). Del-1 expression is
diminished in the gingival tissue of old mice, correlating with hallmarks of periodontitis,
such as excessive neutrophil recruitment and IL-17-dependent inflammatory bone loss
(Eskan et al., 2012). Consistent with this, Del-1-deficient mice develop spontaneous
periodontitis at a young age, accompanied by heavy neutrophil infiltration in the gingiva in a
manner dependent on LFA-1. The periodontitis due to Del-1 deficiency was reversed in
mice with Del-1/LFA-1- or Del-1/IL-17-receptor-double deficiency. Interestingly, local
periodontal treatment with soluble Del-1 in old mice inhibited IL-17 production, LFA-1dependent neutrophil infiltration, and associated bone loss (Eskan et al., 2012). Analysis of
biopsies from patients with periodontitis revealed decreased levels of Del-1 and enhanced
levels of IL-17 in the diseased tissue, as compared to the adjacent healthy tissue, thereby
suggesting that the inflammatory IL-17/Del-1-loop is operative in human periodontitis as
well (Eskan et al., 2012). These findings suggest that Del-1 and IL-17 are reciprocally crossregulated and that Del-1 confers a self-regulated homeostatic control mechanism of
neutrophil recruitment, being constantly ‘on’ to prevent chronic inflammation, but being
turned ‘off’ when neutrophil recruitment is needed. Additionally, local application of Del-1
seems a promising therapeutic strategy to prevent chronic inflammatory bone loss in the
context of periodontitis (Eskan et al., 2012).
More recently, Del-1 was also shown to prevent IL-17-dependent neuroinflammation in the
course of EAE. Specifically, Del-1 expression was reduced in both chronic active MS
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lesions and in the inflamed spinal cord of mice subjected to EAE. Del-1-deficiency resulted
in enhanced EAE disease severity, accompanied by elevated IL-17-dependent neuroinflammation. Interestingly, administration of soluble Del-1 ameliorated progression of
relapsing-remitting EAE (Choi et al., 2014 in press). Together, application of Del-1 may
represent a promising therapeutic approach in IL-17-dependent inflammatory disorders.
Further endogenous inhibitors of inflammatory cell recruitment
Further endogenous inhibitors of leukocyte recruitment have been identified. Pentraxin-3
(PTX-3) is a member of the long pentraxin family of soluble pattern-recognition molecules.
PTX-3 expression in myeloid cells is upregulated in response to TLR signalling and
inflammatory cytokines. In neutrophils, PTX-3 is released from intracellular granules upon
inflammation (Maina et al., 2009). PTX-3 reduces neutrophil rolling by binding to Pselectin, thereby inhibiting the interaction of P-selectin with its leukocyte counter-receptor,
PSGL-1 (Hajishengallis and Chavakis, 2013; Inforzato et al., 2012; Deban et al., 2010). In
accordance with the inhibitory effect of PTX-3 on leukocyte rolling, PTX-3-deficient mice
display increased leukocyte recruitment in a model of acute lung injury (Deban et al., 2010;
Hajishengallis and Chavakis, 2013).
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Growth Differentiation Factor (GDF)-15 is a member of the transforming growth factor
(TGF)-! superfamily. Its tissue expression is increased upon sterile inflammation during
ischemic injury and it acts as an inhibitor of leukocyte extravasation limiting myocardial
tissue damage (Kempf et al., 2006). Moreover it was shown that coronary artery ligation in
Gdf15-deficient mice led to enhanced recruitment of neutrophils into the infarcted
myocardium and an increased incidence of cardiac rupture, while, infusion of recombinant
GDF-15 repressed neutrophil recruitment. The regulatory role of GDF-15 on leukocyte
recruitment is mediated by activation of Cdc42 GTPase and inhibition of Rap1 GTPase, thus
blocking chemokine-induced activation of !2-integrins (Kempf et al., 2011). It remains to be
addressed in more detail, whether factors, such as PTX-3 or GDF-15 could be
therapeutically engaged in preclinical and clinical inflammatory settings.
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Additional endogenous molecules have been described that influence leukocyte recruitment.
Galectin-1 has been demonstrated to down-regulate neutrophil expression of PSGL-1,
CD11b and L-selectin induced by platelet-activated factor in vitro and neutrophil adhesion
to endothelial cells under flow. In turn, increased leukocyte adhesion was observed in the
cremaster model in galectin-1 deficient mice, using intravital microscopy (Cooper et al.,
2008, Herter and Zarbock, 2013).
Annexin 1, a Ca2+ and phospholipid binding protein, is another potent endogenous regulator
of inflammation (Gerke et al., 2005). Annexin 1 is abundant in neutrophils and it is released
upon neutrophil activation (Perretti and Flower, 2004). Several peptides deriving from its Nterminal domain potently inhibit neutrophil recruitment (Perretti et al., 2002). Upon
exposure to the cell surface, annexin 1 interacts with the formyl peptide receptor (FPR), the
high affinity receptor of fMLP, as well as the lipoxin A4 receptor (ALX or FPR-like
receptor) (El Kebir et al., 2008; Perretti and Flower, 2004; Perretti et al., 2002; Perretti,
2003). Glucocorticoids promote annexin 1 synthesis, and annexin 1 is thereby thought to
mediate many of the anti-inflammatory effects of these steroids (Perretti and Flower, 2004).
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Its important role in the regulation of neutrophil recruitment was demonstrated in mice
deficient for annexin 1, which display augmented and prolonged inflammatory reaction and
partial resistance to the anti-inflammatory effect of dexamethasone, during acute or chronic
inflammation (Hannon et al., 2003; Perretti and Flower, 2004). Combined treatment with
aspirin-triggered lipoxins and annexin-1-derived peptides significantly limits neutrophil
infiltration (Perretti et al., 2002).

Conclusion
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Leukocyte integrins constitute major players in inflammatory cell recruitment into sites of
infection and/or tissue injury. Preclinical studies in animal models of inflammation have
indicated that integrin blockade or deficiency may significantly modulate disease initiation
and/or progression. These findings led to the development of antibodies against leukocyte
integrins, which are used in clinical practise for the treatment of patients with severe
inflammatory disorders. However, patients treated with such agents may experience
immunosuppression, and rarely, may suffer from severe infections, including PML. The
identification of endogenous inhibitors, which homeostatically regulate leukocyte
recruitment to inflammatory sites, may have fewer side effects and thus may prove
beneficial as a therapeutic alternative in the treatment of inflammatory syndromes.
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(BBB)

Blood-brain barrier

(CCL)

CC-chemokine ligand

(CAMs)

cell adhesion molecules

(CNS)

central nervous system

(CD)

Crohn’s disease

(CXCL)

CXC-chemokine ligand

(DCs)

dendritic cells

(Del-1)

Developmental endothelial locus-1

(EGF)

epidermal growth factor

(EAE)

experimental autoimmune encephalomyelitis

(GDF)

Growth Differentiation Factor

(GALT)

gut-associated lymphoid tissue

(IBD)

inflammatory bowel diseases
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(LAD-I)

I leukocyte adhesion deficiency

(ICAM-1)

intercellular cell-adhesion molecule 1

(JAM)

Junctional Adhesion Molecule

(LFA-1)

lymphocyte function-associated antigen 1

(Mac-1)

macrophage-1 antigen

(MAdCAM1)

mucosal vascular addressin cell-adhesion molecule 1

(MS)

multiple sclerosis

(PTX-3)

pentraxin-3

(PECAM-1)

platelet/endothelial-cell adhesion molecule 1

(PML)

progressive multifocal leukoencephalopathy

(PSGL-1)

P-selectin glycoprotein ligand-1

(RAGE)

receptor advanced glycation end products

(Treg)

regulatory T cells

(RA)

rheumatoid arthritis

(TLRs)

Toll-like receptors

(UC)

ulcerative colitis

(VCAM)

vascular cell-adhesion molecule

(VLA)

very late antigen
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Figure 1. The multistep model of leukocyte recruitment
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The sequential steps of the leukocyte adhesion cascade and the adhesive interactions
between endothelium and leukocytes are shown. The cascade is initiated with leukocyte
capturing and rolling on the endothelium, followed by chemokine-induced leukocyte
activation, slow rolling, firm leukocyte adhesion/arrest, adhesion strengthening induced by
integrin ligation, crawling and leukocyte transmigration. Essential molecular players
involved in the adhesive processes include: selectins and their glycoprotein ligands,
chemokines and their receptors, integrins and adhesion receptors of the immunoglobulinsuperfamily. "4- and !2-integrins play a critical role in the course of the cascade. Integrin
activation occurs upon chemokine triggered signaling (inside-out signaling) in cooperation
with selectin-activated pathways. Activated integrins contribute to slow rolling, firm
adhesion, crawling and to transendothelial migration.
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Figure 2. Leukocyte integrin targeting in animal inflammatory models
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The role of the !2 integrins "M!2 and "L!2 has been studied in several animal models of
inflammatory disorders. In autoimmune encephalomyelitis (EAE), a rodent model
resembling multiple sclerosis, either treatment with an antibody against CD11b or CD11a or
deficiency in one of these integrins leads to reduced EAE disease severity. Administration of
anti-CD11b or anti-LFA-1 antibodies limits skin manifestations and inflammation in
psoriatic models. In addition, deficiency in the !2 subunit CD18 protects animals from
arthritis development and combined inhibition of CD11b and CD11a leads to significantly
decreased neutrophil recruitment. CD11a blockade has also been linked to decreased bone
loss in inflammatory arthritis models, whereas mice lacking CD11a demonstrate bone loss in
a periodontitis model. Regarding the inflammatory bowel diseases (IBD), CD11b inhibition
leads to reduced inflammatory cell infiltration and less mucosal damage in a model of
colitis.
In addition, !1 integins serve as targets for interevention in inflammatory disease models.
Blockade of "4!1 prevents disease development in an EAE model. Furthermore, T cell
recruitment to the synovium is dependent on "4!1-integrin as shown in a model of arthritis.
Besides "4!1, the inhibition of "1!1-integrin has been shown to be beneficial by inhibiting
disease development in a psoriatic model. In addition, "4!7 blockade attenuates T cell
homing to Peyer’s patches, a main component of gut-associated lymphoid tissue (GALT).
Moreover, treatment with antibodies against either "E!7 or !7 reduces inflammation in a
model of colitis.
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Therapeutic targeting of leukocyte integrins in clinical use.
Disease

Integrin

Drug

Target

Treatment

Multiple
Sclerosis

"4!1

Natalizumab

humanized monoclonal IgG4
antibody against the "4
integrin subunit

Approved for the treatment of
relapsing-remitting multiple
sclerosis

Psoriasis

"L!2

Efalizumab

humanized monoclonal IgG1
antibody against the alpha
chain (CD11a) of "L!2
integrin

Effective in the treatment of
psoriasis (withdrawn in 2009)

Natalizumab

humanized monoclonal IgG4
antibody against the "4
integrin subunit

Approved for the treatment of
medium to severe Crohn’s disease
under restrictive distribution
program (USA)

Vedolizumab

humanized IgG1 monoclonal
antibody against "4!7integrin

Approved for the treatment of
moderate to severe Crohn’s
disease and ulcerative colitis

Etrolizumab

humanized IgG1 monoclonal
antibody against the !7
subunit of "4!7- and "E!7integrins

Effective in the treatment of
moderate to severe ulcerative
colitis (clinical trials)

Inflammatory
Bowel
Disease

"4!7,
"E!7
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